CDKN2A and glioblastoma: Temporal lobe IDH1/2-wild-type GBM cases displayed a divergent profile dominated by TERTp mutations (80%), EGFR amplifications (44%), PTEN deletions (36%), TP53 mutations (32%), and CDKN2A/B deletions (24%) (Fig. 5K).